Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

✍ Scribed by Dino Amadori; Rosella Silvestrini; Mario De Lena; Francesco Boccardo; Andrea Rocca; Emanuela Scarpi; Francesco Schittulli; Mario Brandi; Roberta Maltoni; Patrizia Serra; Riccardo Ponzone; Nicoletta Biglia; Lorenzo Gianni; Amelia Tienghi; Maria Rosaria Valerio; Paola Bonginelli; Laura Amaducci; Marina Faedi; Editta Baldini; Angelo Paradiso

• Publisher: Springer US
• Year: 2010
• Tongue: English
• Weight: 485 KB
• Volume: 125
• Category: Article
• ISSN: 0167-6806
• DOI: 10.1007/s10549-010-1257-5